SecBot SecBot
PRESS-RELEASE ·Filed Apr 1, 2026

COGT

Cogent Biosciences, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Traders should monitor FDA acceptance and review timeline under RTOR, upcoming medical conference data presentation, and potential near-term catalysts from AdvSM NDA submission expected in first half of 2026. Positive regulatory response could drive significant upside.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$35.24
T+0 close · Apr 1, 2026 · via day close
Latest settled
+9.93%
T+60 · $38.74
Vs SPY
−3.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $35.24entry
  2. T+1 · 8mo ago −0.09%α −0.16% · $35.21
  3. T+5 · 7mo ago +5.99%α +2.22% · $37.35
  4. T+20 · 7mo ago +1.79%α −7.93% · $35.87
  5. T+60 · 5mo ago +9.93%α −3.45% · $38.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cogent Biosciences announced the submission of a New Drug Application (NDA) for bezuclastinib in second-line GIST under the FDA's RTOR program, based on positive Phase 3 PEAK trial results showing a 50% reduction in progression risk and 16.5-month median PFS. The drug combination also demonstrated a 46% objective response rate, significantly outperforming sunitinib monotherapy.

Key Facts

  • Submitted NDA for bezuclastinib in imatinib-resistant GIST under FDA's Real-Time Oncology Review (RTOR) program
  • Phase 3 PEAK trial showed 50% reduction in risk of progression or death (HR 0.50) vs sunitinib monotherapy
  • Median PFS of 16.5 months with bezuclastinib combination vs 9.2 months for sunitinib alone
  • Objective response rate (ORR) of 46% vs 26% in control arm
  • Bezuclastinib previously granted Breakthrough Therapy Designation by FDA
  • Full data to be presented at a major medical meeting in first half of 2026
  • Company plans to initiate Phase 2 trial in first-line GIST patients with exon 9 mutations this quarter

Financial Impact

Potential blockbuster revenue if approved; no direct financial figures disclosed but clinical results support high commercial upside

revenuevaluationmarket share

Risk Factors

  • FDA may not approve the NDA or may require additional data
  • Immature overall survival data leaves long-term efficacy uncertain
  • Recent insider selling of $242.6M in the past 30 days raises potential concern about confidence in near-term prospects

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3266534

Track record

13 reports on COGT

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
  4. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  5. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  6. Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  7. Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  8. Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  9. May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
  10. May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026